Redirecting to https://www.astrazeneca-us.com/media/press-releases/2022/enhertu-fam-trastuzumab-deruxtecan-nxki-approved-in-the-us-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer-08052022.html...

Click here if your browser doesn't automatically take you to this page.